Rheumatic manifestations in HIV
Authors:
H. Ciferská; J. Hořínková
Authors‘ workplace:
Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
Published in:
Čes. Revmatol., 27, 2019, No. 1, p. 30-41.
Category:
Review Article
Overview
Diagnosis of Human Immunodeficiency Virus (HIV) infection is still rare in rheumatology outpatient clinics. HIV infection has typically long latent period with a slow progression to the acquired immunodeficiency syndrome (AIDS). Specific rheumatic symptoms associated with HIV infection are painful joint syndrome, HIV-associated arthritis, HIV-associated arthritis and the diffuse infiltrative lymphocytosis syndrome (DILS). Systemic connective tissue disease may develop de novo in HIV patients, and its manifestations may overlap with the manifestations of infection. The overlapping manifestations could delay diagnosis of HIV infection in patients with pre-existing rheumatic disease prior to HIV infection. Retroviral therapy effectively slows down the course of HIV infection. It reduces the prevalence of opportunistic infections and DILS, but it can induce a number of immunological abnormalities. Interestingly, diseases associated with CD4 + lymphocyte activity, such as rheumatoid arthritis or systemic lupus erythematosus are going to remission in the course of HIV infection, but may relapse after effective retrovirus therapy, when level CD4+ rises. This paper will address the characteristics of rheumatic manifestations in HIV infection.
Keywords:
AIDS – systemic disease of the binder – arthritis – DMARD – rheumatic manifestation
Sources
1. Yao Q, Frank M, Glynn M, et al. Rheumatic manifestations in HIV-1 infected in-patients and literature review. Clin Exp Rheumatol 2008; 26(5): 799–806.
2. Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol 2009; 21(4): 404–410.
3. Walker-Bone K, Doherty E, Sanyal K, Churchill D. Assessment and management of musculoskeletal disorders among patients living with HIV. Rheumatology (Oxford) 2017; 56(10): 1648–1661.
4. Boyd MA, Boffito M, Castagna A, et al. Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Med 2019; 20(Suppl 1): 3–11.
5. Worobey M, Telfer P, Souquière S, et al. Island biogeography reveals the deep history of SIV. Science 2010; 329: 1487.
6. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006; 313: 523.
7. Murphey-Corb M, Martin LN, Rangan SR, et al. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 1986; 321: 435.
8. Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts – 16th International AIDS Conference epidemiology plenary. Clin Infect Dis 2007; 44: 981.
9. Marešová M. Zpráva o výskytu a šíření HIV/AIDS za rok 2018. [online] http://www.szu.cz/tema/ prevence/zpravaovyskytuasirenihivaidszarok2018
10. Arasteh K, Des Jarlais DC. Injecting drug use, HIV, and what to do about it. Lancet 2008; 372: 1709.
11. Branson BM, Stekler JD. Detection of acute HIV infection: we can’t close the window. J Infect Dis 2012; 205: 521.
12. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children. Geneva, Switzerland: World Health Organization 2007; 1–48.
13. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS update 2017. http: //www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf
14. Sedaghat AR, Rastegar DA, O’Connell KA, et al. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis 2009; 49: 1763.
15. Zákoucká H. Národní referenční laboratoř pro HIV/AIDS. http://www.szu.cz/ narodnireferencnilaboratorproaids
16. Lawson E, Sabin C, Perry N, Richardson D, et al. Is HIV painful? An epidemiologic study of the prevalence and risk factors for pain in HIV-Infected patients. Clin J Pain 2015; 31(9): 813–819.
17. Parker R, Stein DJ, Jelsma J. Pain in people living with HIV/AIDS: a systematic review. J Int AIDS Soc 2014; 17(1): 18719.
18. Muñoz Fernández S, Cardenal A, Balsa A, et al. Rheumatic manifestations in 556 patients with human immunodeficiency virus infection. Sem Arth Rheum 1991; 21: 30–39.
19. Hochberg MC, Fox R, Nelson KE, et al. HIV infection is not associated with Reiter’s syndrome: data from the Johns Hopkins Multicenter AIDS cohort study. AIDS 1990; 4: 1149–1151.
20. Berman A, Espinoza LR, Diaz JD, et al. Rheumatic manifestations of Human Immunodeficiency Virus infection. Am J Med 1988; 85: 59–64.
21. Marquez J, Restrepo CS, Candia L, et al. Human immunodeficiency virus-associated rheumatic disorders in the HAART era. J Rheumatol 2004; 31: 741–746.
22. Ouédraogo DD, Ntsiba H, et al. Clinical spectrum of rheumatologic diseases in a department of rheumatology in Ouagadougou (Burkina Faso). Clin Rheumatol 2014; 33(3): 385–389.
23. Keruly JC, Chaisson RE, Moore RD. Increasing incidence of avascular necrosis of the hip in HIV-infected patients. J Acquir Immune Defic Syndr 2001; 28: 101–102.
24. Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137(1): 17.
25. Goh SSL, Lai PSM, Tan ATB, et al. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int 2018; 29(3): 595–613.
26. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52: 396.
27. Berman A, Robredo G, Spindler A, et al. Rheumatic manifestations in populations at risk for HIV infection: the added effect of HIV. J Rheumatol 1991; 18: 1564–1567.
28. Cuellar ML, Espinoza LR. Rheumatic manifestations of HIV-AIDS. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 579.
29. Stein CM, Davis P. Arthritis associated with HIV infection in Zimbabwe. J Rheumatol 1996; 23: 506.
30. Ekwom PE, Oyoo GO, Amayo EO, Muriithi IM. Prevalence and characteristics of articular manifestations in human immunodeficiency virus infection. East Afr Med J 2010; 87(10): 408–414.
31. Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter’s syndrome. Arch Derm 1987; 123: 1622–1632.
32. Yao Q, Frank M, Glynn M, Altman RD. Rheumatic manifestations in HIV-1 infected in-patients and literature review. Clin Exp Rheumatol 2008; 26(5): 799–806.
33. Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter’s syndrome: a disease continuum? Arthritis Rheum 1990; 33(10): 1574.
34. Njobvu P, McGill P. Soft tissue rheumatic lesions and HIV infection in Zambians. J Rheumatol 2006; 33: 2493–2497.
35. Bijlsma JWJ, Derksen RHWM, Huber-Brunning O, Borleffs JCC. Does AIDS ‚cure‘ rheumatoid arthritis? Ann Rheum Dis 1988; 47: 350–351.
36. Siva C, Brasington RD. Worsening of arthritis with antiretroviral therapy: the coexistence of rheumatoid arthritis and human immunodeficiency virus infection revisited. J Clin Rheum 2001; 7: 42–46.
37. Du Toit R, Whitelaw D, Taljaard JJ, et al. Lack of specificity of anti-cyclic citrullinated peptide antibodies in advanced human immunodeficiency virus infection. J Rheumatol 2011; 38(6):
1055–1060.
38. Mehsen-Cêtre N, Cazanave C. Osteoarticular manifestations associated with HIV infection. Joint Bone Spine 2017; 84(1): 29–33.
39. Nicholson P, Saunsbury E, D’Angelo S, et al. Prevalence of and risk factors for gout in HIV-positive adults: a case-control study. Int J STD AIDS. doi:10.1177/0956462418799803 [Epub ahead of print].
40. Silverberg MJ, Jacobson LP, French A, et al. Age and racial/ethnic differences in the prevalence of reported symptoms in HIV-infected persons on antiretroviral therapy. J Pain Symptom Manage 2009; 38: 197–207.
41. Chiowchanwisawakit P, Koolvisoot A, Ratanasuwan W, Suwanagool S. Prevalence of rheumatic disease in HIV-infected Thai patients. J Med Assoc Thailand 2005; 88: 1775–1781.
42. Kole AK, Roy R, Kole DC. Musculoskeletal and rheumatological disorders in HIV infection: Experience in a tertiary referral center. Indian J Sex Transm Dis 2013; 34(2): 107–112.
43. Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A, et al. Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. Orphanet J Rare Dis 2017; 12(1): 86.
44. Noe MM, Jain AG, Shahi d S, Majeed U. severe rhabdomyolysis as an unusual presentation of primary human immunodeficiency virus infection. Cureus 2018; 10(7): e3041.
45. Lloyd TE, Pinal-Fernandez I, Michelle EH, et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology 2017; 88(15): 1454–1460.
46. Virot E, Duclos A, Adelaide L, et al. Autoimmune diseases and HIV infection: a cross-sectional study. Medicine (Baltimore) 2017; 96(4): e5769.
47. Robinson-Papp J, Simpson DM. Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve 2009; 40: 1043–1053.
48. Johnson RW, Williams FM, Kazi S, et al. Human immunodeficiency virus-associated polymyositis: a longitudinal study of
outcome. Arthritis Rheum 2003; 49: 172–178.
49. Sagar A, Mohanty AP, Bahal A. Zidovudine-induced myopathy: A study in Indian patients. J Neurosci Rural Pract 2010; 1(2): 63–66.
50. Cupler EJ, Danon MJ, Jay C, et al. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol (Berl) 1995; 90: 1–6.
51. Daikh BE, Holyst MM. Lupus-specific autoantibodies in concomitant human immunodeficiency virus and systemic lupus erythematosus: case report and literature review. Semin Arth Rheum 2001; 30(6): 418–425.
52. Colon M, Martińez DE. Clinical remission of systemic lupus erythematosus after human immunodeficiency virus infection. P R Health Sci J 2007; 26(1): 79–81.
53. Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with ‚lupus-like‘ features: a clinicopathologic study of 14 cases. Kidney Int 2005; 67(4): 1381–1390.
54. Jakez-Ocampo J, Carrillo-Maravilla E, Richaud-Patin Y, et al. An unusual multiplex systemic lupus erythematosus family with high prevalence of nephropathy, late-onset disease, and one member with disease-onset post-HIV therapy. J Clin Rheumatol 2008; 14(1): 34–37.
55. Chetty R. Vasculitides associated with HIV infection. J Clin Pathol 2001; 54(4): 275–278.
56. Chetty R, Batitang S, Nair R. Large artery vasculopathy in HIV-positive patients: another vasculitic enigma. Hum Pathol 2000; 31(3): 374–379.
57. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120: 932.
58. Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58: e1.
59. Djawe K, Buchacz K, Hsu L, et al. Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons – San Francisco, 1981–2012. J Infect Dis 2015; 212: 1366.
60. Basu D, Williams F, Ahn C, Reveille J. Changing spectrum of the diffuse infiltrative lymphocytosis syndrome. Arth Rheum 2006; 55(3): 466–472.
61. Kazi S, Cohen PR, Williams F, et al. The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients. AIDS 1996; 10(4): 385–391.
62. De Silva DJ, Obi AA, Mitchell SM. Bilateral panuveitis in HIV-1-infected patients with CD8 lymphocytosis. Ocul Immunol Inflamm 2005; 13(4): 311–316.
63. Lawson E, Bond K, Churchill D, Walker-Bone K. A case of immune reconstitution syndrome: adult-onset still’s disease in a patient with HIV infection. Rheumatology 2009; 48: 446–447.
64. Fournier A, Martin-Blondel G, Lechapt-Zalcman E, et al. Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review. Front Immunol 2017; 8: 577.
65. Fox C, Walker-Bone K. Evolving spectrum of HIV-associated rheumatic syndromes. Best Pract Res Clin Rheumatol 2015; 29(2): 244–258.
66. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 2008; 9(6): 389–396.
67. Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011; 118(12): 3263–3272.
68. Chiang G, Sassaroli M, Louie M, et al. Inhibition of HIV-1 replication by hydroxychloroquine. Clin Ther 1996; 18(6): 1080–1092.
69. Njobvu PD, McGill PE. Sulphasalazine in the treatment of HIV-related spondyloarthropathy. Br J Rheumatol 1997; 36(3): 403–404.
70. Carroll MB, Fields JH, Clerc PG. Rheumatoid arthritis in patients with HIV: management challenges. Open Access Rheumatol 2016; 8: 51–59.
71. Menon K, Van Voorhees AS, Bebo BF, Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62(2): 291–299.
72. Read SW, DeGrezia M, Ciccone EJ, et al. The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. PLoS One 2010; 5(8): e11937.
73. Schlapfer E, Fischer M, Ott P, Speck RF. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS 2003; 17: 1613–1620.
74. Chamberlain FE, Dinani N, Gurmit K, et al. Azathioprine can be safely used in HIV-infected patients. AIDS 2014; 28: 447–448.
75. Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 2007; 74(2): 197–200.
76. Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67(5): 710–712.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2019 Issue 1
Most read in this issue
- Rheumatic manifestations in HIV
- Risk faktors for development of knee and hip joint osteoarthritis for patients with total endoprosthesis indicated
- Gastrointestinal involvement is systemic sclerosis – the consequences and treatment strategy
- Stanovisko České revmatologické společnosti k personálnímu a technickému vybavení center biologické léčby v revmatologii a ke způsobu organizace jejich sítě